Table 2.
HRT and duration of use by recency | Age group (years) | |||||
---|---|---|---|---|---|---|
50-59 | 60-69 | 70-79 | ||||
Rate per 10 000 | Extra cases | Rate per 10 000 | Extra cases | Rate per 10 000 | Extra cases | |
Never use | 26 | – | 31 | – | 30 | – |
Oestrogen only: | ||||||
Recent use 1-5 years | 29 | 3 | 35 | 4 | 38 | 8 |
Recent use ≥5 years | 28 | – | 36 | 5 | 38 | 8 |
Oestrogen-progestogen: | ||||||
Past use 1-5 years | 25 | – | 33 | 2 | 35 | 5 |
Past use ≥5 years | 24 | – | 36 | 5 | 38 | 8 |
Recent use 1-<5 years | 35 | 9 | 46 | 15 | 49 | 19 |
Recent use ≥5 years | 41 | 15 | 57 | 26 | 66 | 36 |
Tibolone: | ||||||
Recent use 1-<5 years | 28 | – | 35 | 4 | 38 | 8 |
Recent use ≥5 years | 31 | – | 40 | 9 | 45 | 15 |
Rates were estimated using rates in unexposed populations from Clinical Practice Research Datalink multiplied by adjusted odds ratios derived from subgroup analyses for different age categories (see fig 5). Extra cases were reported only for statistically significant findings. Recent use is within one and five years; past use is five years before the index date.